Reagent readiness is an operating system, not an emergency spreadsheet

Shortages are an enterprise risk

FDA explains that medical-device shortages can result from manufacturing and quality problems, geopolitical events, natural disasters, delays, public-health emergencies, and discontinuations. FDA's 506J framework includes strips and reagents among device categories that may require manufacturer notification during or in advance of a public-health emergency.

A healthcare organization cannot prevent every disruption. It can prevent confusion about who decides, what inventory is critical, which alternative is acceptable, and what evidence is required before changing the testing pathway.

• Identify single-source reagents, calibrators, controls, consumables, and service dependencies.
• Define minimum stock, reorder triggers, conservation rules, and escalation owners.
• Pre-map alternate analyzers, reference laboratories, specimen requirements, and turnaround-time effects.
• Keep current validation and verification templates ready so an emergency change does not begin from a blank page.

The hidden cost begins before stock reaches zero

Teams spend hours calling vendors, moving inventory between sites, changing orders, reviewing alternate lots, repeating quality control, adjusting workflows, and explaining delayed results. Those hours rarely appear in the reagent budget.

The organization also carries clinical and reputational risk if a rushed substitution creates unverified performance, inconsistent reference information, unclear communication, or an unstable backup process.

Build a continuity playbook

A useful playbook links supply monitoring to technical and executive action. It should show the affected service, days of supply, demand pattern, substitute options, validation needs, patient impact, financial exposure, communication path, and decision authority.

For high-risk assays, leadership should know the trigger for conservation, the trigger for send-out or platform conversion, and the evidence required to return to normal operations.

• Operational dashboard: stock, burn rate, open orders, vendor status, and affected sites.
• Technical readiness: current IFUs, AMR, QC needs, comparison samples, and approval path.
• Financial view: waste avoided, send-out cost, overtime, service impact, and implementation cost.
• Governance: named owners, meeting cadence, escalation thresholds, and after-action review.

How AssayIQ helps

AssayIQ can facilitate a focused supply-and-continuity review, build the risk register, map alternate testing pathways, prepare validation plans, coordinate approved data analysis, and create a leadership dashboard and implementation roadmap.

The benefit is not a promise that shortages disappear. It is faster, clearer action with quality controls preserved and less dependence on a director or supervisor carrying the entire response alone.